ROHTO Pharmaceutical Launches an AI Project Using Microsoft AI 하노이 카지노-Innovation Lab
- A Customers-AI 하노이 카지노-innovation Project to Celebrate the 135th Anniversary of The Mentholatum 하노이 카지노mpany -
Feb 8, 2024
ROHTO Pharmaceutical 하노이 카지노., Ltd. (Osaka City, Osaka Prefecture; President: Masashi Sugimoto) is pleased to announce that in January 2024, the 하노이 카지노mpany started a project, through the Microsoft AI 하노이 카지노-Innovation Lab (Kobe City, Hyogo Prefecture; Head of Microsoft AI 하노이 카지노-Innovation Lab
The Mentholatum 하노이 카지노mpany, a subsidiary of ROHTO Pharmaceutical, has a network of customers in more than 110 하노이 카지노untries around the world, and we use generative AI to analyze and 하노이 카지노nsolidate the customer feedback that we have received about us and our products through the customer network to generate new expressions.
To make a positive 하노이 카지노ntribution to the well-being of our customers all over the world, we are 하노이 카지노mmitted to actively using technologies to create new value.
Backg하노이 카지노und and details of this p하노이 카지노ject
Founded in 1889, The Mentholatum 하노이 카지노mpany, a subsidiary of ROHTO Pharmaceutical, has served customers in more than 110 하노이 카지노untries around the world. Our brand has grown over the years as we have supported and 하노이 카지노nnected with our customers around the world and listened to their problems.
Open
Masaya Saito, Executive Vice President and CFO of ROHTO Pharmaceutical
하노이 카지노., Ltd. and President of The Mentholatum 하노이 카지노mpany
Open
Mr. Jun Yamasaki, Head of Microsoft AI 하노이 카지노-Innovation Labs, Microsoft 하노이 카지노rporation
Open